logo
  • Über uns
    • Über uns
    • Führungsteam
    • Partnerschaften
    • Unsere Standorte
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Aktieninformation
    • Analysten-Coverage
    • Außerordentliche Hauptversammlung 2023
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Most Referenced Publications

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines


by Sovereign

mRNA mediates passive vaccination against infectious agents, toxins, and tumors


by Sovereign

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial


by Sovereign

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects


by Sovereign

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile


by Sovereign

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals


by Sovereign